IL6 and congenital rubella syndrome: A critical nuance in management is the limited role of tocilizumab in isolated ICANS; while paramount for treating systemic CRS, its large molecular size impedes CNS penetration, and its use can paradoxically elevate circulating interleukin-6 (IL-6) levels, which may potentially exacerbate neuroinflammation [12].